The purpose of this study was to investigate the degree of correlation between sexual dysfunction and depression, anxiety, and somatic symptoms among patients with major depressive disorder (MDD) and to identify the dimension most predictive of sexual dysfunction.
M ental illness has a large effect on sexual function and the expression of sexuality, and many studies have illustrated that sexual dysfunction is significantly associated with depression.
(1-3) Although decreased libido is most often reported, difficulties with arousal resulting in vaginal dryness in women and erectile dysfunction in men and absent or delayed orgasm are also prevalent.
(1-3) These findings have been replicated cross-culturally. (4, 5) Some antidepressants have significant effects on sexual dysfunction. (6) Although there can be side effects of treatment related to sexual dysfunction, some studies have reported improvements in depression and sexual dysfunction after antidepressant treatment. (6) (7) (8) (9) Several studies have reported a relationship between anxiety and sexual dysfunction. (10, 11) In addition, generalized anxiety disorder was found to be associated with a 2.6-fold greater risk of inhibited orgasm and a 2.1-fold greater risk of inhibited sexual excitement in men and women, and a 2.5-fold greater risk of dyspareunia in women. (12) Moreover, sexual arousal may decrease in women with anxiety of a greater severity, (13) and women with sexual desire disorder are more worried and anxious than sexuallyfunctional women. (14) Depression, anxiety, and somatic symptoms are correlated and interacted. Patients with major depressive disorder (MDD) often have multiple comorbid somatic symptoms, (15) (16) (17) and sexual dysfunction has been considered a physical (or somatic) symptom of MDD. Moreover, sexual dysfunction is also common in some painful physical diseases. (18) (19) (20) Therefore, it has been questioned whether sexual dysfunction is the same as or correlated with other somatic symptoms among patients with MDD, such as painful physical symptoms, chest tightness, muscle tension, and other symptoms. Previous studies related to sexual dysfunction and mood disorders have focused on the dimensions of depression and anxiety, (11) but rarely having studies discussed the relationship between sexual dysfunction and other somatic symptoms among patients with MDD. (21) To the best of our knowledge, no study has compared the degree of correlation of sexual dysfunction with depression, anxiety, and somatic symptoms among patients with MDD. Therefore, the purpose of this study was to investigate the degree of correlation of sexual dysfunction with the three dimensions (depression, anxiety, and somatic symptoms) among patients with MDD and to identify the dimension most predictive of sexual dysfunction. Based on the findings of previous studies, (1) (2) (3) (10) (11) (12) we hypothesized that 1) the depression and anxiety dimensions are both correlated with sexual dysfunction, and 2) the depressive dimension might be most correlated with sexual dysfunction among the three dimensions.
METHODS

Subjects
Patients were recruited into this study between January 2004 and January 2005 from the psychiatric outpatient clinic of Chang Gung Memorial Hospital, a medical center in northern Taiwan. This study was approved by the Institutional Review Board of the same hospital. The inclusion criteria were psychiatric outpatients 18-65 years old who had not taken antidepressants or other psychotropic drugs within the previous 2 weeks and who met the DSM-IV text revision (TR) criteria for MDD in a major depressive episode, (22) which was diagnosed by a board-certified psychiatrist using the Structured Clinical Interview for DSM-IV TR Axis I Disorders. (23) To prevent sexual dysfunction from being confounded by other medical conditions, substance abuse, or psychotic symptoms, the following exclusion criteria were established: 1) a history of substance dependence or abuse without full remission in the previous month; 2) psychotic symptoms, catatonic features, or severe psychomotor retardation resulting in obvious difficulty in being interviewed; and 3) chronic medical diseases such as hypertension, diabetes mellitus, and other medical conditions, except for headache. Informed consent was obtained from all participants before enrollment.
Instruments
The Arizona Sexual Experience Scale (ASEX) is a self-administered scale with five questions. It is designed to assess five major aspects of sexual dysfunction, drive, arousal, penile erection/vaginal lubrication, ability to reach orgasm, and satisfaction from orgasm. (24) Items are measured on a 6-point scale (1 to 6), with higher scores reflecting impaired sexual function. This scale allows rapid detection of sexual dysfunction. Sexual dysfunction was defined as 1) a total ASEX score of ≥ 19, 2) any one item with a score of ≥ 5, or 3) any three items with a score of ≥ 4. (24) The reliability and validity of the ASEXChinese Version (ASEX-CV) have been established among patients with MDD by Wen, (25) with a Cronbach alpha of 0.89 and a sensitivity and specificity for predicting sexual dysfunction of 0.74 and 0.84, respectively. Three scales -the Hamilton Depression Rating Scale (HAMD), the Hospital Anxiety and Depression Scale (HADS), and the Depression and Somatic Symptoms Scale (DSSS) -were used to evaluate the severity of depression, anxiety, and somatic symptoms. (26) (27) (28) The DSSS, a self-administered scale, includes 12 items for depression (depression subscale; DS) and 10 items for somatic symptoms (somatic subscale; SS), which includes five pain symptoms and five non-pain somatic symptoms. The validity and reliability of the DSSS have been reported in previous studies. (28) (29) (30) The DS of the DSSS is composed of items regarding common depressive symptoms including fatigue, insomnia, poor appetite, loss of sexual desire, and others. Therefore, the somatic component comprises 33.3% (4/12) of the DS when these four symptoms are included in the somatic component. Within the 17-item HAMD, eight items are related to somatic symptoms, including initial, middle, and terminal insomnia, loss of appetite, loss of weight, general somatic symptoms, somatic anxiety symptoms, and loss of libido; therefore, the somatic component of the HAMD accounts for 34.6% of the total possible HAMD score when the eight items are included. The HADS comprises 7 items for anxiety (HADS-A) and 7 items for depression (HADS-D) and does not include any somatic symptom items. Of the 7 items of the HADS-D, five are markers for an anhedonic state. (31) Both the HAMD and the DS include one item for sexual desire (14 th item in the HAMD and the DS). When testing for a correlation between the ASEX-CV score and depression, anxiety, and somatic symptoms, the item for sexual desire may increase the correlation with the ASEX-CV score. To avoid this confounding effect, the total HAMD and DS scores in the study excluded the score of the item for sexual desire, and for further analysis, the total scores were calculated by adding the 16 remaining items of the HAMD (HAMD 16 ) and the 11 remaining items of the DS (DS 11 ). After subjects were enrolled in the study, they were asked to complete the selfadministered ASEX-CV, DSSS and HADS, and the HAMD was evaluated.
Procedure
The subjects accepted pharmacotherapy after enrollment. In the first four weeks, each patient was administered open-label venlafaxine (extendedrelease) at a fixed dosage of 75 mg (one capsule) per day, which was used because it is effective in the treatment of depression and somatic symptoms. (32) Zolpidem (10 mg per tablet) was prescribed as needed at night (33) as insomnia is a common complaint in patients with MDD. Subjects were told that venlafaxine could be shifted to another antidepressant at any visit after the first if they were not able to tolerate it. Four weeks later, the subjects were invited to attend a follow-up, at which the ASEX-CV, the DSSS and the HADS were completed again and the HAMD was reevaluated by the same psychiatrist. The improvement percentage (IP) was calculated as (score at baseline -score post treatment)/score at baseline, of each scale or subscale.
Statistical methods
All statistical analyses were performed using SPSS 15.0 for Windows (SPSS Inc., Chicago, Illinois, U.S.A.). The independent t-test, paired t-test, chi-square test, and Pearson's correlation were used where appropriate. The independent t-test was used for comparison of continuous variables of the incomplete group and complete group at baseline; the chisquare test was used for comparison of categorical variables of the incomplete group and complete group at baseline. The paired t-test was used for the comparison of continuous variables at baseline v.s. at endpoint for the complete group. To identify the most powerful scales or subscales in terms of predicting the ASEX-CV score at baseline and the onemonth follow-up, multiple linear regression with forward selection was employed. This method has two advantages: 1) it can be used to identify the variables that most effectively predict the total ASEX-CV score and 2) it can prevent multicolinearity. In the regression models, the dependent variable was the total score of the ASEX-CV at baseline or follow-up. The independent variables were the scores of the three scales (the HAMD 16 , the DS 11 , the SS, the HADS-D, and the HADS-A scores) at the same time points and five patient variables, age, gender, years of education, marital status, and occupation. In all statistical analyses, a p value < 0.05 was considered statistically significant.
RESULTS
During the study period, 135 patients (34 men, 101 women) were enrolled at baseline and 95 (70.4%) subjects completed the one-month treatment course. Thirty (22.2%; 30/135) subjects did not complete the ASEX-CV scale at baseline and 20 (21.1%; 20/95) did not complete the scale at the one-month follow-up because these subjects did not engage in sexual activity in the month previous to enrollment. Overall, the 65 (48.1%) subjects who did not complete the one-month pharmacotherapy or the ASEX-CV were categorized into the incomplete group. The other 70 (51.9%) subjects who completed the onemonth pharmacotherapy and the ASEX-CV at both baseline and follow-up were categorized into the complete group. Among the 70 subjects, 58 (82.9%) were treated with venlafaxine, 8 (11.4%) were shifted to paroxetine, and 4 were shifted to another antidepressant because of inability to tolerate the side effects of venlafaxine.
The scores of the three psychometric scales and the patient variables of the two groups are shown in Table 1 . There were no significant differences in the HAMD, DS, SS, HADS-D, HADS-A, and patient variables between the incomplete and the complete group, except that subjects in the incomplete group were younger (28.1 8.7 vs. 32.1 7.6; p < 0.01) ( Table 1) . At endpoint, the scores of the HAMD 16 DS 11 , SS, HADS-D and HADS-A were significantly improved (Table 1) . Moreover, the items for sexual desire in the HAMD (1.1 0.8 vs. 0.9 0.8; p = 0.02) and the DS (1.7
1.0 vs. 1.0 1.1; p < 0.01) were also significantly improved (not shown in tables). Table 2 shows the scores for each ASEX-CV item, which demonstrate that no significant improve- Correlation of each ASEX-CV item with the three psychometric scales at baseline and onemonth follow up Table 3 shows the correlation of each ASEX-CV item with the three psychometric scales at baseline. The HADS-D was significantly correlated with the 2 nd , 3 rd , and 4 th items and the total ASEX-CV score. The DS 11 was significantly correlated with the 3 rd and 4 th items. The HAMD 16 , the SS, and the HADS-A were not significantly correlated with any of the ASEX-CV items nor with the total score. Table 4 presents the correlation of each ASEX-CV item with the three psychometric scales after the one-month treatment. The HADS-D and the DS 11 were significantly correlated with each item and the total score of the ASEX-CV, with the exception item 5 on the DS 11 . The HAMD 16 and the HADS-A were significantly correlated with the total score and some items of the ASEX-CV. The SS was not significantly correlated with any item of the ASEX-CV.
At the two points, the HADS-D tended to be correlated with the most ASEX-CV items, followed by the DS 11 and the HAMD 16 . The SS was not correlated with any of the ASEX-CV items. Among the five items, item 5 of the ASEX-CV was not correlated with any of the three psychometric scales except for the HADS-D at endpoint.
Independent factors associated with the total score of the ASEX
The HADS-D was the only factor found to independently predict the total ASEX-CV score at baseline (Beta = 0.27; p = 0.02) and at endpoint (Beta = 0.46; p < 0.001) (not shown in tables). The final R square for the regression model at baseline was 0.13, which was partially explained by the HADS-D (R square change = 0.08). This means that the HADS-D score explained 8% of the variance of the total ASEX-CV score at baseline. The final R square for the regression model at endpoint was 0.18, which was fully explained by the HADS-D (not shown in tables). This means that the HADS-D score explained 18% of the variance of the total ASEX-CV score at endpoint. Both at baseline and endpoint, the HADS-D was the only significant predictor of the total ASEX-CV score and subjects with higher HADS-D scores were more likely to have higher ASEX-CV scores. That is, the subjects with severe depression had worse sexual function. The HAMD, DS, SS, HADS-A, and other demographic variables were not entered into the three regression models.
DISCUSSION
Among the three psychometric scales, the HADS-D was the only subscale entered into the regression models to independently predict the total score of the ASEX-CV after controlling for patient variables at baseline and posttreatment. The HADS-D was correlated with more individual ASEX-CV items than the HAMD 16 and the other subscales at the two points. The clinical implications arising from our results were as follows: 1) sexual dysfunction was more correlated with depression than with anxiety and somatic symptoms; 2) the ASEX-CV was not correlated with the SS at either of the two points.
The HADS-D was more correlated with ASEX-CV score than the HAMD 16 , and the DS 11 . This might result from the fact that the HAMD 16 and the DS 11 also include several somatic symptoms, such as fatigue, insomnia, decreased appetite or weight, and other somatic anxiety symptoms. However, the HADS-D, which is especially focused on the anhedonic state, (31) does not include any somatic symptoms. In fact, previous studies have reported that sexual dysfunction among patients with depression is strongly correlated with an anhedonic state. (12, 34) As described above, sexual dysfunction may be more related to the anhedonic component of depression than to the somatic component of depression. Our results implied that pharmacotherapy for MDD should be more focused on depression, especially the anhedonic state, when improvement of sexual dysfunction is an important issue for patients with MDD.
Several points are worthy of note, (1) The IP of the total score of the ASEX-CV was negative (-1.6 24.7). However, the IPs of the three psychometric scales were positive (HAMD 16 34.7 25) . Previous studies have reported that improvement of sexual dysfunction is related to improvement of depression among patients with MDD. (35) One previous study suggested that genital symptoms (level of sexual interest or ease of sexual arousal) showed a later response to antidepressant treatment than depressed mood and general somatic symptoms. (21) It is also possible that the negative IP of the total ASEX-CV score may be a result of sexual function being affected by the side effects of antidepressant treatment (36) during the 4 weeks of pharmacotherapy. (2) At baseline and endpoint, the 5 th item of the ASEX-CV (satisfaction from orgasm) was not significantly correlated with depression, anxiety, and somatic symptoms, except for the HADS-D at the 4-week point. Some studies have reported that satisfaction from orgasm is related to the relationship with the partner, perception of the partner's sexual dysfunction (20) and frequency of sexual intercourse.
(37) (3) Although the changes in the five items and the total score of the ASEX-CV were not significant at endpoint, the scores of the 2 nd , 3 rd , and 4 th items were increased by a small degree at endpoint, which implied that the three items may be more apt to be affected by antidepressant side effects. In fact, a recent meta-analysis illustrated that antidepressants affect specific phases (including desire, arousal and orgasm) of sexual function, (38) which is compatible with our results.
There were several methodological issues or limitations in this study. (1) Our study enrolled MDD outpatients in a medical center using several exclusion criteria. Some subjects did not complete the ASEX-CV because they did not engage in sexual activity in the month previous to enrollment. In the first month, venlafaxine was prescribed at a fixed dosage, however, 12 subjects were shifted to other antidepressants in the complete group. Bias might therefore have been introduced during this enrollment and treatment process. (2) The study was a single-site study with a limited number of participants. (3) The treatment duration was selected as four weeks, because this time point has been reported as being one of the important milestones after which treatment response can be predicted or observed. (39, 40) Although an early treatment response is a predictive factor of late prognosis, (41) the short treatment duration, which was not sufficient to correct sexual dysfunction due to the symptoms of depression, might be one of the reasons for a lack of improvement in the ASEX-CV score. Moreover, the adverse effects of treatment were also a possible reason for the lack of improvement in the ASEX-CV score. (4) Our subjects were patients with MDD. It is unknown whether the relationships between sexual dysfunction, depression, anxiety, and somatic symptoms differ in other populations. Moreover, different antidepressants might also affect the IPs of different dimensions post-pharmacotherapy. (5) In our study, 71.4% of the participants were women, so there may be some gender bias in the results. (6) Although it has been reported that venlafaxine has a lower rate of sexual dysfunction than serotonin-specific reuptake inhibitors, (6) it still had the potential side effect of sexual dysfunction. Therefore, using venlafaxine in this study might have caused bias.
In conclusion, the total ASEX-CV score was most correlated with the depressive dimension (anhedonic state) of MDD. The ASEX-CV score was not correlated with somatic symptoms. Further studies to explore the relationships between sexual dysfunction, depression, anxiety, and somatic symptoms in other populations may be indicated. 
